Benchmark analyst Josh Sullivan reiterates Ultralife (NASDAQ:ULBI) with a Buy and maintains $12 price target.
- Headlines
- Benchmark Reiterates Buy on Ultralife, Maintains $12 Price Target
Benchmark Reiterates Buy on Ultralife, Maintains $12 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
16:31
On December 5th, 2023, the onshore RMB against the US dollar closed at 7.2610 at 16:30, an increase of 78 points compared to the previous trading day.
16:29
The National Development and Reform Commission: support local governments in taking practical measures to promote ice and snow tourism consumption, explore the establishment of local ice and snow days and special holidays.
16:27
The FDA has approved AstraZeneca's best-selling drug Imfinzi for the treatment of limited-stage small cell lung cancer.
AZN-1.87%